Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Carsten, Goessl"'
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2012, Iss 6, Pp 287-303 (2012)
Externí odkaz:
https://doaj.org/article/e018c85c32b74aabbfb13eaa626b8137
Autor:
Matthew R. Smith, Christophe Massard, Janet E. Brown, Lawrence Karsh, Piotr Milecki, Stéphane Oudard, H. Wang, Neal D. Shore, Ronaldo Damião, Michael Rader, Carsten Goessl, Karim Fizazi, Michael A. Carducci, Wendy Ying
Publikováno v:
European Urology. 68:42-50
Previous studies have reported on prognostic factors for castration-resistant prostate cancer (CRPC); however, most of these studies were conducted before docetaxel chemotherapy was approved for CRPC.To evaluate the prognostic value of multiple param
Autor:
Neal D. Shore, Gavin Marx, Paul Sieber, Fred Saad, Carsten Goessl, Juan Morote, Stéphane Oudard, Ronaldo Damião, Peter J. Van Veldhuizen, Karim Fizazi, Zhishen Ye, Matthew R. Smith, Roger Dansey, Kurt Miller, Bertrand Tombal
Publikováno v:
Journal of Clinical Oncology. 31:3800-3806
Purpose Denosumab, an anti–RANK ligand monoclonal antibody, significantly increases bone metastasis–free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and delays time to first bone metastasis in men with nonmetastatic castration-resistant pr
Autor:
Carsten Goessl, Matthew R. Smith, Benjamin Z. Leder, Fred Saad, Chunlei Ke, Blair Egerdie, Teuvo L.J. Tammela, Paul Sieber
Publikováno v:
Journal of Clinical Oncology. 30:3271-3276
Purpose To characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT). Patients and Methods We prospectively evaluated LBM in a prespecified substudy of a randomized controlled trial of denos
Autor:
Roger Dansey, Leonid Katz, William C. Dougall, Paul J. Kostenuik, Holly Brenza Zoog, Rachel B. Wagman, Ada Braun, Carsten Goessl
Publikováno v:
Annals of the New York Academy of Sciences. 1263:29-40
Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone
Autor:
Teuvo L.J. Tammela, Benjamin Z. Leder, Matthew R. Smith, Paul Sieber, Fred Saad, Carsten Goessl, Roger Dansey, R B Egerdie, Jiri Heracek, Chunlei Ke
Publikováno v:
Prostate Cancer and Prostatic Diseases. 15:308-312
Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of
Autor:
Roger Dansey, Lawrence Karsh, Neal D. Shore, Piotr Milecki, Janet E. Brown, Ronaldo Damião, Michael Rader, H. Wang, Karim Fizazi, Qi Jiang, Sylvia Tadros, Matthew R. Smith, Carsten Goessl, Michael A. Carducci
Publikováno v:
The Lancet. 377:813-822
Summary Background Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases f
Publikováno v:
BJU International. 101:1071-1075
Newly formed bone in the typically osteoblastic bone metastases from prostate cancer shows characteristics of woven bone, e.g. marked defects in mineralization and microstructure. Adding to the reduced mechanical strength of prostate cancer bone meta
Autor:
Arif Hussain, David L. Bilhartz, Richard J. Cook, Ronald Linnartz, Marc Gittelman, Y. J. Hei, Matthew R. Smith, Ming Zheng, Eric J. Small, Chris Wynne, Claude Schulman, Carsten Goessl, Fred Saad, Robin Murray, Fairooz F. Kabbinavar, Celestia S. Higano, Norman Zinner
Publikováno v:
Journal of Clinical Oncology. 23:2918-2925
Purpose To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy. Patients and Methods: The 201 patients in this report were the placebo control group from an abo
Publikováno v:
Der Urologe. 42:660-668
Ziel der molekularen Diagnostik in der Onkologie ist der fruhzeitige Nachweis einer Tumorerkrankung im Rahmen der Primardiagnostik oder der Tumornachsorge. Als Ausgangsmaterial fur eine nichtinvasive Diagnostik dienen Korperflussigkeiten. Neben den e